Vall d’Hebron leads a global project to improve the treatment against Chagas disease, with NANOMOL as partner
The Vall the Hebron Research Institute (VHIR) leads an international Project for the development of a more effective and cheaper drug, for the treatment of Chagas disease that also helps to reduce the number of undesirable side effect of actual therapies.
The Vall the Hebron Research Institute (VHIR) leads an international Project for the development of a more effective and cheaper drug, for the treatment of Chagas disease that also helps to reduce the number of undesirable side effect of actual therapies. Coordinated by Dr. Israel Molina, one of the maximum world experts in Chagas and member of the infectious diseases research group of VHIR, the project BERENICE is financed by the 7th framework program of the European Commission. The 4 years project counts with the participation of prestigious European and South-American entities.
The project BERENICE, acronym of BEnznidazol and triazol Research group for Nanomedicine and Innovation on Chagas disease (Benznidazol and triazol research group for the nanomedicine and innovation in Chagas disease), will reformulate a existing drug, the Benznidazol, for the obtaining of a safer toxicity profile and to increment its efficacy. The design of the new nano- or micro- encapsulated formulation will be developed by CIBBER-BBN, in which are integrated the research groups NANOMOL-CSIC (ICMAB) and NANOBIOCEL from the University of Basque Country. Molecular Magnetism.
